Literature DB >> 18792814

beta-lactam susceptibility of Escherichia coli isolates from urinary tract infections exhibiting different resistance phenotypes.

M Lerma1, L Cebrián, Mj Giménez, P Coronel, M Gimeno, L Aguilar, J García de Lomas.   

Abstract

Susceptibility to beta-lactams was determined in 203 recent Spanish E. coli isolates from urinary tract infections exhibiting different resistance phenotypes: a) susceptible (n = 60); b) quinolone-resistant (n = 45); c) penicillinase (n=64); d) hyperproduction of penicillinase (n=8); e) inhibitor resistant TEM (IRT) (n=18), and f) extended spectrum betalactamase (ESBL) (n=8).Minimum inhibitory concentration (MIC) determination by agar dilution and susceptibility tests for ESBL detection by macrodilution were performed following CLSI recommendations. All the beta-lactams tested showed high activity against susceptible and penicillinase phenotypes, with close to 100 % susceptibility. Hyperproduction of penicillinase increased MIC90 values for all antibiotics except for meropenem, with 100% resistance to cefuroxime and amoxicillin/clavulanic acid, and 100% susceptibility to cefotaxime, piperacillin/tazobactam and meropenem. All the antibiotics, except for amoxicillin/clavulanic acid, exhibited high activity against IRT. Meropenem, cefminox and piperacillin/tazobactam exhibited the highest activity against ESBL, followed by amoxicillin/clavulanic acid. The most active compound among the parenteral antibiotics was meropenem, regardless of the resistance phenotype. Among the oral antibiotics, the most active compound was cefditoren with the exception of ESBL where amoxicillin/clavulanic acid where the MIC90 value was one dilution lower.

Entities:  

Mesh:

Year:  2008        PMID: 18792814

Source DB:  PubMed          Journal:  Rev Esp Quimioter        ISSN: 0214-3429            Impact factor:   1.553


  2 in total

1.  Determination of MIC distribution of arbekacin, cefminox, fosfomycin, biapenem and other antibiotics against gram-negative clinical isolates in South India: a prospective study.

Authors:  Sangeetha Rajenderan; Veeraraghavan Balaji; Shalini Anandan; Rani Diana Sahni; Giannoula S Tansarli; Matthew E Falagas
Journal:  PLoS One       Date:  2014-07-28       Impact factor: 3.240

2.  Simultaneous gut colonisation and infection by ESBL-producing Escherichia coli in hospitalised patients.

Authors:  Johny Asir; Shashikala Nair; Sheela Devi; Kenchappa Prashanth; Rajagopalan Saranathan; Reba Kanungo
Journal:  Australas Med J       Date:  2015-06-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.